CN105833251A - Hand and foot chapping nursing composition and preparing method thereof - Google Patents
Hand and foot chapping nursing composition and preparing method thereof Download PDFInfo
- Publication number
- CN105833251A CN105833251A CN201610288535.2A CN201610288535A CN105833251A CN 105833251 A CN105833251 A CN 105833251A CN 201610288535 A CN201610288535 A CN 201610288535A CN 105833251 A CN105833251 A CN 105833251A
- Authority
- CN
- China
- Prior art keywords
- parts
- pedis
- care composition
- rhagadia manus
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title abstract description 6
- 230000000474 nursing effect Effects 0.000 title abstract description 5
- 239000000341 volatile oil Substances 0.000 claims abstract description 38
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229930003231 vitamin Natural products 0.000 claims abstract description 21
- 235000013343 vitamin Nutrition 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 21
- 229940088594 vitamin Drugs 0.000 claims abstract description 21
- 239000004378 Glycyrrhizin Substances 0.000 claims abstract description 17
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 17
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 17
- 229940022757 asiaticoside Drugs 0.000 claims abstract description 17
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 17
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 17
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 17
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 17
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 17
- 229940026510 theanine Drugs 0.000 claims abstract description 17
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 16
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 16
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 16
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 16
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 15
- 229920000615 alginic acid Polymers 0.000 claims abstract description 15
- 102000015696 Interleukins Human genes 0.000 claims abstract description 14
- 108010063738 Interleukins Proteins 0.000 claims abstract description 14
- 210000002683 foot Anatomy 0.000 claims description 41
- 241000905957 Channa melasoma Species 0.000 claims description 34
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 32
- 241000196324 Embryophyta Species 0.000 claims description 24
- 239000000758 substrate Substances 0.000 claims description 19
- 239000002674 ointment Substances 0.000 claims description 17
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 16
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- 230000003647 oxidation Effects 0.000 claims description 16
- 238000007254 oxidation reaction Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000004890 Interleukin-8 Human genes 0.000 claims description 12
- 108090001007 Interleukin-8 Proteins 0.000 claims description 12
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 12
- 229940096397 interleukin-8 Drugs 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 6
- 241000218645 Cedrus Species 0.000 claims description 6
- 240000003553 Leptospermum scoparium Species 0.000 claims description 6
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 6
- 239000010678 thyme oil Substances 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 244000178870 Lavandula angustifolia Species 0.000 claims description 5
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 238000002663 nebulization Methods 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 14
- 206010052428 Wound Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 230000017074 necrotic cell death Effects 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 abstract 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 230000003260 anti-sepsis Effects 0.000 abstract 1
- VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000007766 cera flava Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 229940083037 simethicone Drugs 0.000 description 4
- 229940075582 sorbic acid Drugs 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 239000004334 sorbic acid Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 208000001387 Causalgia Diseases 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a hand and foot chapping nursing composition and a preparing method thereof .The hand and foot chapping nursing composition is mainly prepared from, by weight, 2-8 parts of sphingolipid, 1-5 parts of glycyrrhizin, 2-4 parts of asiaticoside, 3-6 parts of acetylsalicylic acid, 1-2 parts of theanine, 0.2-0.3 part of interleukin, 1-2 parts of oleanolic acid, 3-8 parts of sugar alcohol, 0.5-1.5 parts of beta-oxidized juglone, 3-6 parts of plant essential oil, 1-4 parts of water soluble vitamin and 3-6 parts of alginic acid .By combining the components in certain proportion, the functions of antisepsis and anti-inflammation, anti-infection, relieving swelling, pains and itching, removing necrosis, promoting granulation, promoting blood circulation, avoiding cicatrization and beautifying and nursing skin are realized, and then quick healing of chapped wounds is accelerated .The composite has a remarkable clinical treatment effect.
Description
Technical field
The present invention relates to technical field, be specifically related to a kind of rhagadia manus et pedis care composition and preparation method thereof.
Background technology
Rhagadia manus et pedis refers to hand and foot xerosis cutis and the crackle caused by a variety of causes, with pain, seriously
Person can affect daily life and work.Primary disease is some dermopathic simultaneous phenomenons, is also a kind of independent
Dermatosis.
The reason causing rhagadia manus et pedis is broadly divided into endogenous cause of ill and exopathogenic factor, and endogenous cause of ill is that horny layer is thicker, at the palm sole of the foot etc.
Position spy is thick, easily ftractures, and the palm sole of the foot is without hair follicle and sebaceous gland, and temperature is low and time humidity is less in the winter time,
The skin lacking sebum protection is just susceptible to cracking;The additionally situation such as old people, ichthyosis and seborrheic keratosis,
Easily causing xerosis cutis, horny layer more thickens, more susceptible disease under the influence of some extraneous factors.Exopathogenic factor is
Outside brothers are exposed to, both hands often in contact with various materials, as being dried, friction, wound, it is easy to by acid,
Alkali, organic solvent fat melting effect, and fungus, antibacterial etc. invade cause infection.In life, work,
, easily there is chapped skin in the tractive of activities.
Rhagadia manus et pedis is apt to occur in autumn and winter season.Erythra be distributed in finger bend side, palm, heel, foot the sole of the foot outside etc.
Cuticle thickening or the position often rubbed against, clinical manifestation is the depth along dermatoglyph development, different in size splitting
Gap, from without any, skin lesion can feel that slight twinge or moderate are touched a tender spot, or even causalgia with hemorrhage.
The most conventional medicine includes the medicines such as external Plaster for reunion of laceration of skin, glycerol liniment, 15% carbamide ointment.As
Fruit is chapped hemorrhage, the degree of causalgia, preferably with hot water by affected part maceration, make skin moisturizing, with blade by angle
Matter blocked up place skiving, external used medicine the most again.But all there is the inapparent shortcoming of curative effect in existing medicine.
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of rhagadia manus et pedis care composition and preparation method thereof.
The technical scheme is that a kind of rhagadia manus et pedis care composition, by weight, mainly by
Following component forms: sphingolipid 2-8 part, glycyrrhizin 1-5 part, Asiaticoside 2-4 part, aspirin
3-6 part, theanine 1-2 part, interleukin 0.2-0.3 part, oleanolic acid 1-2 part, sugar alcohol 3-8
Part, beta oxidation Folium Juglandis quinone 0.5-1.5 part, plants essential oil 3-6 part, water soluble vitamins 1-4 part, algae
Glue acid 3-6 part.
Further, described interleukin IL-β and interleukin 8 are by arbitrarily than the mixture of composition.
Further, described water soluble vitamins is that vitamin B1, vitamin B2 and vitamin C are by arbitrarily
Mixture than composition.
Further, described plants essential oil be tea tree ethereal oil, lavandula angustifolia essence, fir essential oil, thyme oil,
Cedrus deoclar (Roxb.) G. Don quintessence oil, chamomile essential oil press (3-6): (2-4.5): (2-2.5): (1-2): (1-1.8): the weight of (1-1.2)
Amount is than the mixture of composition.
A kind of rhagadia manus et pedis care composition, its preparation method is:
(1) by described proportioning weigh sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine,
Interleukin, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins,
Algin acid;
(2) by described sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine, interleukin 8
Element, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins, algin acid mix
After conjunction, stir, be crushed to 1-10 μm with supersonic jet mill, obtain admixed finepowder;
(3) described plants essential oil nebulization is uniformly sprayed on the admixed finepowder of step (2) gained,
I.e. obtain rhagadia manus et pedis care composition.
Further, this care composition is prepared as ointment.
Further, the preparation method of described ointment is: weigh 20-30 part substrate, first by described hands
Care composition of chapping enough joins in the substrate of 1/3, and described substrate is by simethicone, Cera Flava, Laurel
Alcohol sodium sulfate forms according to the proportions of 1:4:10, grinds to form fine and smooth pasty state, adds 0.1-0.2 part and prevents
Rotten agent sorbic acid, 0.1-0.2 part antioxidant gallic acid alkyl ester and the substrate of residue 2/3, continue to grind into powder
Uniformly, ointment is i.e. made.
The invention has the beneficial effects as follows: in the present composition, sphingolipid is that the important composition of biofilm structure becomes
Point, it is the critically important bioactive molecule of a class, they participate in regulation growths of cell, differentiation, aging and cell journey
Many important signal transduction processes such as sequence is dead;Glycyrrhizin has antiinflammatory, antiallergic and protecting film knot
Structures etc. act on;Asiaticoside has promotion Wound Healing, is used for treating wound, operation wound, burns,
Keloid and scleroderma;Aspirin has antipyretic, analgesia, antiinflammatory, rheumatism and antiplatelet and gathers
Many pharmacological actions such as collection, play drug effect rapid, and drug effect is certainly;Theanine has the merit of calmness of releiving
Effect;Beta oxidation Folium Juglandis quinone has preferable antiinflammatory bactericidal action, controls wound infection;Water soluble vitamins
Rehabilitation to body has important effect, appropriate vitimin supplement when of wound, contribute to wound and
Time healing, moreover it is possible to provide body resistance, play pre-aseptic effect;Tea tree ethereal oil has sterilization and disappears
Scorching, convergence pore, the effect for the treatment of suppurative wound, Herba Lysimachiae foenum-graeci quintessence oil can with wrinkle removal skin care, promote impaired group
Knitting the function that regeneration recovers, fir essential oil can be releived pain, promotes wound healing, and thyme oil is permissible
Help wound healing, treatment eczema and pimples skin quality, activating brain cell, antibacterial, spasmolytic, anti-insect poison
Liquid, sterilizing, keep fit, promote the effect that scabs, Cedrus deoclar (Roxb.) G. Don quintessence oil has a significant antiinflammation, antibacterial, convergence,
Diuresis, softness, reduce phlegm, antifungal, chamomile essential oil can promote the healing of the wound of inflammation, ulcer.
Help improve eczema, pimples, herpes, chronic eczema, hypersensitization skin, and general allergic phenomena, calm down brokenly
The blood capillary split, promotes elasticity, and strengthening tissue is splendid to being dried the skin easily itched.The above composition presses one
Fixed proportioning combination, energy anti-inflammation, infection, reduces swelling and alleviating pain and pruritus, removes necrosis
And granulation promoting, blood circulation promoting is avoided cicatrization, is beautified and skin nursing, thus reaches to rapidly promote chap
The function of the wound healing split, clinical efficacy is notable.
Detailed description of the invention
Embodiment 1:
A kind of rhagadia manus et pedis care composition, by weight, mainly consists of the following composition: sphingolipid 2
Part, glycyrrhizin 1 part, Asiaticoside 2 parts, aspirin 3 parts, theanine 1 part, interleukin 8
Element 0.2 part, oleanolic acid 1 part, sugar alcohol 3 parts, beta oxidation Folium Juglandis quinone 0.5 part, plants essential oil 3 parts,
Water soluble vitamins 1 part, algin acid 3 parts.
Wherein, described interleukin IL-β and interleukin 8 are by arbitrarily than the mixture of composition.Institute
Stating water soluble vitamins is that vitamin B1, vitamin B2 and vitamin C are by arbitrarily than the mixture of composition.
Described plants essential oil is tea tree ethereal oil, lavandula angustifolia essence, fir essential oil, thyme oil, Cedrus deoclar (Roxb.) G. Don quintessence oil, ocean
Flos Chrysanthemi quintessence oil presses the mixture of the weight ratio composition of 3:2:2:1:1:1.
The preparation method of this rhagadia manus et pedis care composition is:
(1) by described proportioning weigh sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine,
Interleukin, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins,
Algin acid;
(2) by described sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine, interleukin 8
Element, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins, algin acid mix
After conjunction, stir, be crushed to 1 μm with supersonic jet mill, obtain admixed finepowder;
(3) described plants essential oil nebulization is uniformly sprayed on the admixed finepowder of step (2) gained,
I.e. obtain rhagadia manus et pedis care composition.
Again this care composition being prepared as ointment, preparation method is: weigh 20 parts of substrate, first by described
Rhagadia manus et pedis care composition joins in the substrate of 1/3, and described substrate is by simethicone, Cera Flava, the moon
Lauryl sulfate forms according to the proportions of 1:4:10, grinds to form fine and smooth pasty state, adds 0.1 part of anticorrosion
Agent sorbic acid, 0.1 part of antioxidant gallic acid alkyl ester and the substrate of residue 2/3, continue to grind into powder uniformly,
I.e. make ointment.
Using method: clean behind affected part with normal saline, takes appropriate ointment uniform application in affected part,
0.5g/cm2, note protecting wound no longer by secondary injury.
Embodiment 2:
A kind of rhagadia manus et pedis care composition, by weight, mainly consists of the following composition: sphingolipid 5
Part, glycyrrhizin 3 parts, Asiaticoside 3 parts, aspirin 4.5 parts, theanine 1.5 parts, the thinnest
Born of the same parents' interleukin 0.25 part, oleanolic acid 1.5 parts, sugar alcohol 5.5 parts, beta oxidation Folium Juglandis quinone 1.0 parts, plant
Thing quintessence oil 4.5 parts, water soluble vitamins 2.5 parts, algin acid 4.5 parts.
Wherein, described interleukin IL-β and interleukin 8 are by arbitrarily than the mixture of composition.Institute
Stating water soluble vitamins is that vitamin B1, vitamin B2 and vitamin C are by arbitrarily than the mixture of composition.
Described plants essential oil is tea tree ethereal oil, lavandula angustifolia essence, fir essential oil, thyme oil, Cedrus deoclar (Roxb.) G. Don quintessence oil, ocean
Flos Chrysanthemi quintessence oil presses the mixture of the weight ratio composition of 4.5:3.75:2.25:1.5:1.4:1.1.
The preparation method of this rhagadia manus et pedis care composition is:
(1) by described proportioning weigh sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine,
Interleukin, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins,
Algin acid;
(2) by described sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine, interleukin 8
Element, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins, algin acid mix
After conjunction, stir, be crushed to 5.5 μm with supersonic jet mill, obtain admixed finepowder;
(3) described plants essential oil nebulization is uniformly sprayed on the admixed finepowder of step (2) gained,
I.e. obtain rhagadia manus et pedis care composition.
Again this care composition being prepared as ointment, preparation method is: weigh 25 parts of substrate, first by described
Rhagadia manus et pedis care composition joins in the substrate of 1/3, and described substrate is by simethicone, Cera Flava, the moon
Lauryl sulfate forms according to the proportions of 1:4:10, grinds to form fine and smooth pasty state, adds 0.15 part and prevents
Rotten agent sorbic acid, 0.15 part of antioxidant gallic acid alkyl ester and the substrate of residue 2/3, continue to grind into powder uniformly,
I.e. make ointment.
Using method: clean behind affected part with normal saline, takes appropriate ointment uniform application in affected part,
0.35g/cm2, note protecting wound no longer by secondary injury.
Embodiment 3:
A kind of rhagadia manus et pedis care composition, by weight, mainly consists of the following composition: sphingolipid 8
Part, glycyrrhizin 5 parts, Asiaticoside 4 parts, aspirin 6 parts, theanine 2 parts, interleukin 8
Element 0.3 part, oleanolic acid 2 parts, sugar alcohol 8 parts, beta oxidation Folium Juglandis quinone 1.5 parts, plants essential oil 6 parts,
Water soluble vitamins 4 parts, algin acid 6 parts.
Wherein, described interleukin IL-β and interleukin 8 are by arbitrarily than the mixture of composition.Institute
Stating water soluble vitamins is that vitamin B1, vitamin B2 and vitamin C are by arbitrarily than the mixture of composition.
Described plants essential oil is tea tree ethereal oil, lavandula angustifolia essence, fir essential oil, thyme oil, Cedrus deoclar (Roxb.) G. Don quintessence oil, ocean
Flos Chrysanthemi quintessence oil presses the mixture of the weight ratio composition of 6:4.5:2.5:2:1.8:1.2.
The preparation method of this rhagadia manus et pedis care composition is:
(1) by described proportioning weigh sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine,
Interleukin, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins,
Algin acid;
(2) by described sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine, interleukin 8
Element, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins, algin acid mix
After conjunction, stir, be crushed to 10 μm with supersonic jet mill, obtain admixed finepowder;
(3) described plants essential oil nebulization is uniformly sprayed on the admixed finepowder of step (2) gained,
I.e. obtain rhagadia manus et pedis care composition.
Again this care composition being prepared as ointment, preparation method is: weigh 30 parts of substrate, first by described
Rhagadia manus et pedis care composition joins in the substrate of 1/3, and described substrate is by simethicone, Cera Flava, the moon
Lauryl sulfate forms according to the proportions of 1:4:10, grinds to form fine and smooth pasty state, adds 0.2 part of anticorrosion
Agent sorbic acid, 0.2 part of antioxidant gallic acid alkyl ester and the substrate of residue 2/3, continue to grind into powder uniformly,
I.e. make ointment.
Using method: clean behind affected part with normal saline, takes appropriate ointment uniform application in affected part,
0.2g/cm2, note protecting wound no longer by secondary injury.
The clinical observation on the therapeutic effect of medicine of the present invention
1, physical data: accept out-patient's totally 86 example for medical treatment.
2, diagnostic criteria: rhagadia manus et pedis is apt to occur in autumn and winter season.Erythra be distributed in finger bend side, palm, heel,
Cuticle thickening or the position that often rubs against such as outside the foot sole of the foot, clinical manifestation is the depth along dermatoglyph development, length
The short crack differed, from without any, skin lesion can feel that slight twinge or moderate are touched a tender spot, or even causalgia and with
Hemorrhage.According to the clinical characters of skin lesion, the most diagnosable, carry out if desired Mycology examination, antibacterial culturing and
Patch test.
3, Therapeutic Method: first disease sites normal saline is cleaned up;Ointment with embodiment 2 preparation
It is coated with uniformly in affected part, 2-3 time on the 1st, continuous coating 5-7 days.
4, efficacy assessment standard:
Effective: rhagadia manus et pedis symptom is fully recovered, recover normal.
Take a turn for the better: rhagadia manus et pedis disease states alleviates, and the state of an illness progressively takes a turn for the better.
Invalid: not reach improvement standard person.
5, therapeutic outcome (see table):
Total number of persons/people | Effective/people | Improvement/people | Invalid/people | Effective percentage/% |
86 | 75 | 9 | 2 | 97.67 |
In above-mentioned treatment, by Drug therapy rhagadia manus et pedis patient 86 example of the present invention, effective 75 examples of result,
Obvious effective rate is 87.21%, and take a turn for the better 2 examples, and improvement rate is 10.47%, invalid 2 examples, and total effective rate is
95.74%.
Although embodiment of the present invention are disclosed as above, but it is not restricted to description and embodiment
Using listed by, it can be applied to various applicable the field of the invention completely, for being familiar with this area
For personnel, it is easily achieved other amendment, is therefore being limited without departing substantially from claim and equivalency range
Under fixed general concept, the present invention is not limited to specific details.
Claims (7)
1. a rhagadia manus et pedis care composition, it is characterised in that by weight, mainly by following
One-tenth is grouped into: sphingolipid 2-8 part, glycyrrhizin 1-5 part, Asiaticoside 2-4 part, aspirin 3-6
Part, theanine 1-2 part, interleukin 0.2-0.3 part, oleanolic acid 1-2 part, sugar alcohol 3-8 part,
Beta oxidation Folium Juglandis quinone 0.5-1.5 part, plants essential oil 3-6 part, water soluble vitamins 1-4 part, algin acid
3-6 part.
2. a kind of rhagadia manus et pedis care composition as claimed in claim 1, it is characterised in that described white thin
Born of the same parents interleukin IL-β and interleukin 8 are by arbitrarily than the mixture of composition.
3. a kind of rhagadia manus et pedis care composition as claimed in claim 1, it is characterised in that described water-soluble
Property vitamin be vitamin B1, vitamin B2 and vitamin C by arbitrarily than the mixture formed.
4. a kind of rhagadia manus et pedis care composition as claimed in claim 1, it is characterised in that described plant
Quintessence oil is tea tree ethereal oil, lavandula angustifolia essence, fir essential oil, thyme oil, Cedrus deoclar (Roxb.) G. Don quintessence oil, chamomile essential oil
The mixture formed by a certain percentage.
5. a kind of rhagadia manus et pedis care composition as claimed in claim 1, it is characterised in that preparation method
For:
(1) by described proportioning weigh sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine,
Interleukin, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, plants essential oil, water soluble vitamins,
Algin acid;
(2) by described sphingolipid, glycyrrhizin, Asiaticoside, aspirin, theanine, interleukin 8
After element, oleanolic acid, sugar alcohol, beta oxidation Folium Juglandis quinone, water soluble vitamins, algin acid mixing, stirring
Uniformly, it is crushed to 1-10 μm with supersonic jet mill, obtains admixed finepowder;
(3) described plants essential oil nebulization is uniformly sprayed on the admixed finepowder of step (2) gained,
I.e. obtain rhagadia manus et pedis care composition.
The preparation method of a kind of rhagadia manus et pedis care composition the most as claimed in claim 5, it is characterised in that
This care composition is prepared as ointment.
The preparation method of a kind of rhagadia manus et pedis care composition the most as claimed in claim 5, it is characterised in that
The preparation method of described ointment is: weigh 20-30 part substrate, first by described rhagadia manus et pedis care composition
Join in the substrate of 1/3, grind to form fine and smooth pasty state, add 0.1-0.2 part preservative, 0.1-0.2
Part antioxidant and the substrate of residue 2/3, continue to grind into powder uniformly, i.e. make ointment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610288535.2A CN105833251A (en) | 2016-05-03 | 2016-05-03 | Hand and foot chapping nursing composition and preparing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610288535.2A CN105833251A (en) | 2016-05-03 | 2016-05-03 | Hand and foot chapping nursing composition and preparing method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105833251A true CN105833251A (en) | 2016-08-10 |
Family
ID=56590846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610288535.2A Pending CN105833251A (en) | 2016-05-03 | 2016-05-03 | Hand and foot chapping nursing composition and preparing method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105833251A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108014033A (en) * | 2018-01-04 | 2018-05-11 | 湖北瑞晟生物有限责任公司 | The sufficient essential oil of one kind shield and its preparation process |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943545A (en) * | 2006-10-17 | 2007-04-11 | 王海龙 | Cosmetics composite and its preparing method and use |
CN101322750A (en) * | 2008-06-04 | 2008-12-17 | 张小平 | Novel use of Cistanche tubulosa extract |
CN101795732A (en) * | 2007-04-19 | 2010-08-04 | 玫琳凯有限公司 | Magnolia extract containing compositions |
CN103961615A (en) * | 2014-05-23 | 2014-08-06 | 梁亮 | Traditional Chinese medicine composition for treating rhagadia manus and pedalis and preparation thereof |
-
2016
- 2016-05-03 CN CN201610288535.2A patent/CN105833251A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943545A (en) * | 2006-10-17 | 2007-04-11 | 王海龙 | Cosmetics composite and its preparing method and use |
CN101795732A (en) * | 2007-04-19 | 2010-08-04 | 玫琳凯有限公司 | Magnolia extract containing compositions |
CN101322750A (en) * | 2008-06-04 | 2008-12-17 | 张小平 | Novel use of Cistanche tubulosa extract |
CN103961615A (en) * | 2014-05-23 | 2014-08-06 | 梁亮 | Traditional Chinese medicine composition for treating rhagadia manus and pedalis and preparation thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108014033A (en) * | 2018-01-04 | 2018-05-11 | 湖北瑞晟生物有限责任公司 | The sufficient essential oil of one kind shield and its preparation process |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6027728A (en) | Herbal skin regeneration composition and method | |
US10596148B2 (en) | Topical compositions for treatment of psoriasis | |
CN105395467B (en) | A kind of Chinese medicine composition, skin beautifying cosmetic and its application | |
WO2008140200A1 (en) | External compositions for the skin | |
CN101182430A (en) | Health-care multipurpose washing liquor and method for making same | |
CN108042641A (en) | A kind of Chinese medicine acne eliminating cream and preparation method thereof | |
CN102895156B (en) | Skin cream for curing chapped skin and preparation method for skin cream | |
CN110831566A (en) | Skin care compositions | |
KR101114161B1 (en) | Body Detergent composition for moisturizing or soothing the skin containing Aloe barbadensis miller extract and Althaea officinalis root extract | |
CN101313940B (en) | Traditional Chinese medicine nourishing skin-protection cream | |
US8591960B2 (en) | Composition and method for treating bedsores, cuts and burns | |
CN105833251A (en) | Hand and foot chapping nursing composition and preparing method thereof | |
CN115518127A (en) | Antibacterial, anti-inflammatory, detumescence and itching relieving cream and preparation method thereof | |
CN115364022A (en) | Mud film and preparation method thereof | |
US20040131704A1 (en) | A method of organic and all natural treatment, prevention and relief of diaper dermatitis and other related skin irritations. | |
Trinkle | Amish culture and their utilization of burns and wounds ointment for the treatment of burns | |
Hadfield et al. | The use of marigold therapy for podiatric skin conditions | |
CN101229258B (en) | Antianaphylaxis antiphlogistin | |
CN109432211B (en) | Traditional Chinese medicine composition for psoriasis and eczema, external medicine thereof, and preparation methods and application of traditional Chinese medicine composition and external medicine | |
CN103007034A (en) | Traditional Chinese medicine composition used for treatment of residual second-degree burn wound, and preparation method thereof | |
CN112870140A (en) | Anti-allergy itching-relieving composition, skin-care gel, and preparation method and application thereof | |
Khan et al. | Therapeutic approach of unani medicine in the management of psoriasis (Da-us-sadaf) | |
US20200061144A1 (en) | Composition and Method of Skin Relief Cream useful for Eczema, Psoriasis, Lipoma, Burn Wounds, Scars, Keloids, Shingles, Dry Skin Disorders, and Skin Allergies. | |
KR102420354B1 (en) | Lotion composition having circulation and vitality and the manufacturing method thereof | |
RU2128990C1 (en) | Anti-inflammatory and wound-healing ointment "vundehil" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |